Literature DB >> 21616522

Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests.

Jacek J Sznurkowski1, Anton Żawrocki, Janusz Emerich, Katarzyna Sznurkowska, Wojciech Biernat.   

Abstract

OBJECTIVE: Regulatory T cells (Tregs), and the enzyme indoleamine 2,3-dioxygenase (IDO), have potential regulatory properties for immune escape in cancer. Inhibitors of IDO are available and could potentially be used in vulvar cancer if IDO was proved to drive progression of the disease. The aim of this study was to evaluate the expression of factor forkhead boxP3 (FOXP3), a marker of Tregs, and IDO in vulvar squamous cell carcinoma (vSCC), and to verify their prognostic significance.
METHODS: 76 primary tumors and 35 lymph node metastases derived from 76 patients with full clinical history were analyzed. The intratumoral infiltration of Tregs and IDO expression within cancer were evaluated by immunohistochemistry.
RESULTS: The number of Tregs in primary tumor and in corresponding lymph node metastasis was significantly correlated. Intensity of Treg infiltrates in the primary and metastatic sites was not correlated to IDO expression and had no influence on the overall patient survival. High IDO expression was associated with significantly worse overall survival among vSCC patients and was found to be an independent prognostic factor similarly to the tumor grade and patient's age.
CONCLUSIONS: The degree of intratumoral Treg infiltrates is an individual feature and remains stable throughout the course of the disease without impact on the patient's survival. IDO expression predicts shorter survival of vSCC patients. If immunologic tolerance of the tumor is promoted by the overexpression of IDO it will not influence the number of intratumoral Tregs. IDO expression seems to be an independent prognostic factor in patients with vSCC.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21616522     DOI: 10.1016/j.ygyno.2011.04.050

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

Review 1.  Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.

Authors:  Diwakar Davar; Nathan Bahary
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

2.  Host-microbiome interactions: the aryl hydrocarbon receptor as a critical node in tryptophan metabolites to brain signaling.

Authors:  Ning Ma; Ting He; Lee J Johnston; Xi Ma
Journal:  Gut Microbes       Date:  2020-05-13

Review 3.  Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.

Authors:  Simona Maria Fragomeni; Frediano Inzani; Anna Fagotti; Luigi Della Corte; Stefano Gentileschi; Luca Tagliaferri; Gian Franco Zannoni; Giovanni Scambia; Giorgia Garganese
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-25       Impact factor: 4.553

Review 4.  Immunological Relevance of the Coevolution of IDO1 and AHR.

Authors:  Merja Jaronen; Francisco J Quintana
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

5.  The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer.

Authors:  Jacek J Sznurkowski; Anton Żawrocki; Wojciech Biernat
Journal:  BMC Cancer       Date:  2016-07-13       Impact factor: 4.430

6.  PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.

Authors:  Jacek J Sznurkowski; Anton Żawrocki; Katarzyna Sznurkowska; Rafał Pęksa; Wojciech Biernat
Journal:  Oncotarget       Date:  2017-09-15

7.  High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.

Authors:  Kim E Kortekaas; Saskia J Santegoets; Ziena Abdulrahman; Vanessa J van Ham; Marij van der Tol; Ilina Ehsan; Helena C van Doorn; Tjalling Bosse; Mariëtte I E van Poelgeest; Sjoerd H van der Burg
Journal:  J Immunother Cancer       Date:  2019-09-03       Impact factor: 13.751

8.  Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Jacek Jan Sznurkowski; Anton Zawrocki; Wojciech Biernat
Journal:  Cancer Immunol Immunother       Date:  2013-12-25       Impact factor: 6.968

9.  Local immune response depends on p16INK4a status of primary tumor in vulvar squamous cell carcinoma.

Authors:  Jacek J Sznurkowski; Anton Żawrocki; Wojciech Biernat
Journal:  Oncotarget       Date:  2017-07-11

10.  Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology.

Authors:  Thomas Hecking; Thore Thiesler; Glen Kristiansen; Kirsten Kübler; Cynthia Schiller; Jean-Marc Lunkenheimer; Tiyasha H Ayub; Andrea Rohr; Mateja Condic; Mignon-Denise Keyver-Paik; Rolf Fimmers; Jutta Kirfel; Walther Kuhn
Journal:  Oncotarget       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.